

Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma

Shiori Kinoshita,¹ Takashi Ishida,^{1,2} Asahi Ito,¹ Tomoko Narita,¹ Ayako Masaki,^{1,3} Susumu Suzuki,⁴ Takashi Yoshida,¹ Masaki Ri,¹ Shigeru Kusumoto,¹ Hirokazu Komatsu,¹ Norio Shimizu,⁵ Hiroshi Inagaki,³ Taruho Kuroda,⁶ Arne Scholz,⁷ Ryuzo Ueda,⁴ Takaomi Sanda⁸ and Shinsuke Iida¹

¹Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan; ²Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Japan; ³Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Japan; ⁴Department of Tumor Immunology, Aichi Medical University School of Medicine, Japan; ⁵Department of Virology, Division of Medical Science, Medical Research Institute, Tokyo Medical and Dental University, Japan; ⁶Bayer Yakuhin, Ltd., Osaka, Japan; ⁷Bayer AG Pharmaceuticals Division, Berlin, Germany; ⁸Cancer Science Institute of Singapore, National University of Singapore

©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.191395

Received: February 15, 2018.

Accepted: July 30, 2018.

Pre-published: August 3, 2018.

Correspondence: itakashi@iwate-med.ac.jp

SUPPLEMENTAL INFORMATION

Article title:

Cyclin-dependent kinase 9 as a novel specific molecular target in NK cell leukemia/lymphoma

Authors:

Shiori Kinoshita¹, Takashi Ishida^{1,2}, Asahi Ito¹, Tomoko Narita¹, Ayako Masaki^{1,3}, Susumu Suzuki⁴, Takashi Yoshida¹, Masaki Ri¹, Shigeru Kusumoto¹, Hirokazu Komatsu¹, Norio Shimizu⁵, Hiroshi Inagaki³, Taruho Kuroda⁶, Arne Scholz⁷, Ryuzo Ueda⁴, Takaomi Sanda⁸, Shinsuke Iida¹.

Institutions:

¹Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, ²Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University, ³Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, ⁴Department of Tumor Immunology, Aichi Medical University School of Medicine, ⁵Department of Virology, Division of Medical Science, Medical Research Institute, Tokyo Medical and Dental University, ⁶Bayer Yakuhin, Ltd, ⁷Bayer AG Pharmaceuticals Division, ⁸Cancer Science Institute of Singapore, National University of Singapore.

ANKL patient A

49 years old, female


• G-banding

A: 46,X,add(X)(q22)	2/20
B: 47,XX,+X,add(7)(p11.2)	2/20
C: 46,XX	16/20

• Immunophenotype

positive: CD2, CD16, CD56
negative: CD3, CD4, CD5, CD7, CD8 CD19, CD20

• Southern blotting of EBV



ANKL patient B

82 years old, male


• G-banding

A: 45,-Y,add(X)(p11.2), add(3)(p21),del(6)(q?), der(9)del(9)(p?)add(9)(q22), add(11)(q23), add(11)(q23)del(13)(q?), del(14)(q22),add(16)(p13.1), add(17)(p11.2), -18,+mar	4/18
B: 46,XY	14/18

• Immunophenotype


positive: CD2, CD3, CD56
negative: CD4, CD5, CD7 CD8, CD16 CD19, CD20

• Southern blotting of EBV



Supplemental Figure S1.

Supplemental Figure S1. Clinical characteristics of ANKL patients. Clinical characteristics of ANKL patients A and B are shown. These ANKL cells were obtained from the affected BM of the patients, and tested by SRL Inc., (Tokyo, Japan) as part of the clinical work-up. In Southern blotting analyses, M, 1, 2, and 3 indicate size markers, positive control sample, negative control sample, and the patient's sample, respectively, confirming the clonal integration of the EBV genome in the leukemia cells in both cases.



Supplemental Figure S2.

Supplemental Figure S2. Phosphorylation status of RNAPII at the Ser2 site in tumor cells of ENKTL, nasal type, and healthy lymphocytes. The phosphorylation status of RNAPII at the Ser2 site in 12 biopsied tumor lesions of ENKTL, nasal type, was determined by immunostaining using an anti-RNA polymerase II CTD repeat YSPTSPS (phospho S2) antibody (ab5095, abcam, Cambridge). Eight dissected lymph nodes from other cancer surgeries, which were confirmed not to contain cancer metastases (i.e. reactive lymph nodes), were also immunostained by ab5095. **(A)(B)(C)** Phosphorylation status of RNAPII at the Ser2 site in biopsied tumor lesions of ENKTL, nasal type. The two panels on the left show HE staining, and the two on the right show immunostaining by antibodies to phospho-RNAPII (Ser2). Scale bars in the upper two panels represent 1.0 mm, and in the lower two panels, 200 μ m. **(D) (E) (F)** Phosphorylation status of RNAPII at the Ser2 site in non-tumor lymphocytes in the reactive lymph nodes. The two panels on the left show HE staining, and the two on the right show immunostaining by antibodies to phospho-RNAPII (Ser2). Scale bars in the upper two panels represent 1.0 mm, and in the lower two panels, 200 μ m.